US FTC Removing ‘Handcuffs’ To Pursue Pharma Companies, PBMs For Antitrust Violations
Agency staff has more freedom to launch investigations under resolutions approved at Commission’s first meeting under new chair. Mergers and rebate walls expected to be major priorities.
You may also be interested in...
Agency restores long dormant enforcement of section of FTC Act prohibiting businesses from using ‘unfair methods of competition,’ expanding types of corporate behavior subject to enforcement action.
After motion to advance fails at 17 February meeting, proposed study design will be revamped, not scrapped. Despite the 2-2 deadlock on the vote, commissioners uniformly expressed an interest in proceeding with research on PBM industry, focusing on the leading players.
Congressional Republicans and biopharma stakeholders support legislation clarifying the Federal Trade Commission’s authority to assess monetary penalties but argue the House legislation needs guardrails.